with >99% monoclonality assurance in just days.
Replace 8-12 weeks of challenging well plate steps with Opto™ CLD on the Beacon® optofluidic system. In Cell Line Development (CLD), you are looking for the rare, high-producing clones. For the greatest genetic diversity, you need to screen thousands of cells. The Opto CLD workflow screens thousands of clones with ease in less than a week.
Select top clones for even non-traditional antibody molecules.
The Opto CLD Workflow selects top clones by measuring growth and titers over multiple days of on-chip culture. SpotLight™ assays enable quantification of both traditional and non-traditional antibodies, such as Fc-engineered mAbs, bispecifics, and multispecifics.
The Berkeley Lights Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance – which is equivalent to four rounds of limiting dilution!
Unlike traditional well-plate approaches, the Opto CLD Workflow provides a visual record of all clones – in an automated fashion – and allows confident assessment of monoclonality. Cells can be visually tracked from the moment they are loaded into NanoPen™ chambers through culture, antibody secretion assays, and eventual recovery of top secreting clones. Imaging provides information about cell size, morphology, and growth rates for all clones over multiple days of on-chip culture.
Spotlight assay: Simultaneous, quantitative antibody titer measurements on thousands of clones (LEFT). Clones selected based on titer measurements on the Beacon system had 1.5–3-fold higher titers than clones selected using traditional clone picking technology when scaled up to shake flask fed-batch cultures (RIGHT). ©2019 Catalent, Inc. All rights reserved.
Find out how the Opto™ CLD workflow lets you generate the best production cell lines for complex antibody therapeutics with >99% monoclonality assurance in just days.
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.
This poster explains how automated Cell Line Development with greater than 99% monoclonality can be achieved on the Beacon system.